Loading…
← CockpitCompetitor Analysis › SLDB Solid Biosciences Inc.Open in the cockpit ↗

Solid Biosciences Inc.SLDBCompetitor analysis, valuation and peers

United States · USD·Health Care›Biotechnology
Momentum weak 33
Mkt cap
$709M
US dollars, full cap
Free float
82%
of shares outstanding
$/day
$8.31M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
n/a
WACC 18.0%
Hurdle
n/a
no reverse DCF
Next earnings
118 days
16 Mar 2027
Close · USD$6.35
1D+1.9%
1W-16.4%
1M-0.8%
3M-30.2%
6M-1.9%
YTD+12.6%
1Y+46.3%
ATR %7.6%
Beta2.07
52w lowhigh44.5% off high

What Solid Biosciences does

Employees: 121

Solid Biosciences at a glance

Size Solid Biosciences (SLDB) is a United States Health Care company (Biotechnology) with a market value of $709M, the 2452nd largest of 3,085 United States companies the cockpit tracks. Shares closed at $6.35 on 18 Nov 2026.

Performance Over six months the shares fell 1.9%, against -24.8% for the median peer and -2.2% for the United States market (cap-weighted) — 5th highest of 19 in its peer set.

Short interest Short interest is 11.9% of the free float (30 Oct 2026).

Next results Next results expected around 16 Mar 2027 (exchange calendar; dates can move).

Relative performance

10015021 May 202621 Aug 202618 Nov 2026SLDB 98Peer median 76
Six months, rebased to 100: Solid Biosciences against the median of its 20 peers (local-currency closes).

Solid Biosciences financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$0$0$0$0$8.09M
Revenue growth———-100%—
Gross profit-$1.67M-$1.64M-$2.46M-$2.58M$5.69M
EBITDA-$220M-$178M-$127M-$102M-$92.0M
Net income-$215M-$174M-$125M-$96.0M-$86.0M
Free cash flow-$200M-$157M-$101M-$95.7M-$101M
Capital expenditure$1.38M$1.15M$654,000$1.51M$3.02M
Total debt$19.6M$21.2M$24.2M$26.3M$28.5M

Quarterly statements and history in the cockpit →

Solid Biosciences competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+500%+1,000%-25%0%+25%+50%ATTO301333PRME301520AURAKURA772999666882219887SNDXGLUESLDB6-month return →1-month return →
Up and to the right = strong over both horizons. Solid Biosciences is the large dot.

Solid Biosciences competitors and peer comparison

How Solid Biosciences compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Solid Biosciences against its 20 peers (data as of 18 Nov 2026)
MeasureSLDBPeer medianRank in peer set
1-month return-0.8%-7.1%6th highest of 21
6-month return-1.9%-24.8%5th highest of 19
Distance from 52-week high-44.5%-47.7%9th highest of 21

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Solid Biosciences SLDBUnited States$709M-2%n/an/an/an/an/a
Attovia Therapeutics ATTOUnited States$710M+1,325%n/a-5,945%220.7×n/an/a
Shaanxi Micot Pharmaceutical Technology 2335.HKHong Kong$715Mn/an/an/an/an/an/a
R&G PharmaStudies 301333.SZChina$722M-11%+21%11%3.4×17.3%+11.8%
Prime Medicine PRMEUnited States$695M+35%+18%-2,584%105.4×n/an/a
Apnimed APMDUnited States$726Mn/a+380%-140%10.8×n/an/a
Anhui Wanbang Pharmaceutical Technology 301520.SZChina$684M+74%-15%-8%14.7×44.8%+14.7%
Beijing SL Pharmaceutical 002038.SZChina$736M-20%-4%-119%6.9×-13.5%-10.9%
Aura Biosciences AURAUnited States$743M-4%n/an/an/an/an/a
Kura Oncology KURAUnited States$674M-29%-24%-394%2.6×n/an/a
Steminent Biotherapeutics 7729.TWOTaiwan$668M+292%n/an/an/an/an/a
Alphamab Oncology 9966.HKHong Kong$666M-38%-32%-38%6.7×n/an/a
Frontier Biotechnologies 688221.SSChina$658M-48%+153%-20%11.4×40.3%+21.5%
Inventiva IVA.PAFrance$763M-36%-100%-307,063%12,169.8×n/an/a
Nanjing Leads Biolabs 9887.HKHong Kong$764M-50%n/a-108%21.1×n/an/a
Shouyao Holdings Beijing 688197.SSChina$653M-26%+4,564%-92%38.1×n/an/a
Syndax Pharmaceuticals SNDXUnited States$771M-57%+160%-62%3.2×n/an/a
Monte Rosa Therapeutics GLUEUnited States$775M-51%-61%-214%3.3×n/an/a
Wuhan Keqian Biology 688526.SSChina$780M-24%-22%20%4.4×7.8%+2.4%
Geron GERNUnited States$638M-21%+19%-8%2.8×n/an/a
Shenzhen Weiguang Biological Products 002880.SZChina$633M-27%0%18%4.4×n/an/a

Questions

Which companies are Solid Biosciences's closest peers?
The cockpit's peer set: Attovia Therapeutics (ATTO), Shaanxi Micot Pharmaceutical Technology (2335.HK), R&G PharmaStudies (301333.SZ), Prime Medicine (PRME), Apnimed (APMD), Anhui Wanbang Pharmaceutical Technology (301520.SZ), Beijing SL Pharmaceutical (002038.SZ), Aura Biosciences (AURA).
How has Solid Biosciences stock performed?
Over six months to 18 Nov 2026 the shares returned -1.9% against -24.8% for the median peer; over one year +46.3%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.